Monitor for the IND submission in Q4 2026 and the initiation of the first-in-human study in Q1 2027 as key catalysts. The appointment of a seasoned oncology drug developer is a positive signal for regulatory strategy, but the company remains pre-revenue with no new capital raise announced.
Price Chart
Executive Summary
Ernexa Therapeutics announced the appointment of Dr. Robert J. Spiegel to its Board of Directors and provided a pipeline update in its CEO Corner series. The company is targeting an IND submission for lead candidate ERNA-101 in Q4 2026 and a first-in-human study in Q1 2027, with preclinical data showing complete tumor clearance and 100% survival in an ovarian cancer model when combined with anti-PD-1.
Key Facts
- Dr. Robert J. Spiegel appointed to Board of Directors; brings over 25 years at Schering-Plough Research Institute, including as Chief Medical Officer.
- Lead program ERNA-101 is being developed for platinum-resistant ovarian cancer, designed to deliver immune-enhancing cytokines via iMSCs.
- IND submission for ERNA-101 targeted for Q4 2026; first-in-human study initiation targeted for Q1 2027.
- Preclinical data in an ovarian cancer model showed ERNA-101 in combination with anti-PD-1 demonstrated complete tumor clearance and 100% survival.
- Company is also advancing next-generation assets ERNA-102 and ERNA-103.
- No financial data, revenue, or funding information was disclosed in the press release.
Financial Impact
No financial figures disclosed; preclinical-stage company with no revenue.
Risk Factors
- Preclinical-stage company with no approved products or revenue; high execution risk.
- IND submission and clinical trial timelines may be delayed.
- Competition in the cell therapy space for solid tumors is intense.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers